

Together, we can change the current standard of care for pancreatitis with



PANOQUELL®-CA1

(fuzapladib sodium for injection)

The **first FDA conditionally approved** innovative solution for acute canine pancreatitis (ACP).

Infiltration of neutrophils is a hallmark of ACP. ACP ranges in severity from mild to severe.

You never know where it could go.

PANOQUELL®-CA1 inhibits the infiltration of neutrophilic inflammation within the pancreas that occurs in ACP. It is fast and effective by significantly reducing clinical signs associated with ACP. This will aid in reducing time and stress often seen in the hospital setting with ACP treatment.

Take the "ITIS" out of pancreatitis

User Safety Warnings: Not for use in humans. Keep this medication out of reach of children. Limited data is available on the potential teratogenic effects of fuzapladib.

In case of accidental self-injection, skin contact, eye exposure, or accidental ingestion refer to the package insert.

To obtain a Safety Data Sheet, report suspected adverse drug experiences, or for technical assistance, contact Ceva Animal Health at 1-800-999-0297.

For additional information about reporting adverse drug experiences for animal drugs, contact FDA at 1-888-FDA-VETS or at www.fda.gov/reportanimalae.

 **PANOQUELL®-CA1**
(fuzapladib sodium for injection)

14 mg fuzapladib sodium per vial
4 mg/mL when reconstituted

For intravenous use in dogs only.
Reconstitute before using.

PANOQUELL®-CA1 is a leukocyte function-associated antigen 1 (LFA-1) activation inhibitor.

Indication: For the management of clinical signs associated with acute onset of pancreatitis in dogs.

Conditionally approved by FDA pending a full demonstration of effectiveness under application number 141-567. It is a violation of Federal law to use this product other than as directed in the labeling.

CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian.



Benefits:

- Fast and Effective
- Safe
- Cost Effective



Scan QR to learn more about PANOQUELL®-CA1

Available to order!
Reach out to your local
CEVA territory manager.

PANOQUELL®-CA1 is conditionally approved by FDA pending a full demonstration of effectiveness under application number 141-567. It is a violation of Federal Law to use this product other than as directed in the labeling.

PANOQUELL® is a registered trademark of Ishihara Sangyo Kaisha, Ltd.



©2023 Ceva Animal Health, LLC.
PAN-104-23v2